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Dan Cheng1,2, Huimin Shi1,2, Kan Zhang1,2, Lingling Yi1,2 and Guohua Zhen1,2*Abstract
Objectives: RAD51 gene plays an important role in the pathogenesis of squamous cell carcinoma of the head and
neck (SCCHN), colorectal cancer, ovarian cancer and acute leukaemia. A number of studies assessed the association
between RAD51 135G/C polymorphism and the risk of these cancers in different population. However, the results
have been inconclusive. We performed a systematic meta-analysis to evaluate the association between RAD51
135G/C polymorphism and the risk of these four types of cancer.
Methods: Pubmed, Cochrane library and Chinese Biomedical Literature Database (CBM) were searched for
case-control studies on RAD51 135G/C polymorphism and the risk of SCCHN, colorectal cancer, ovarian cancer and
acute leukaemia published up to Oct 31, 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to
assess the strength of association.
Results: A total of twenty-two published studies, with 6836 cases and 8507 controls were included. Overall, no
significant association was found between RAD51 135G/C polymorphism and the risk of the four types of cancers
(G/G vs. C/C: OR = 0.83, 95% CI: 0.43-1.59, P = 0.57). However, there was a significant association between this
polymorphism and SCCHN risk in the subgroup analysis by cancer type (G/G vs. C/C: OR = 2.46, 95% CI: 1.08-5.61,
P = 0.03).
Conclusion: The RAD51 135G/C polymorphism was associated with the risk of SCCHN.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1383180234106945.
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Cancer is one of the most common fatal diseases, which
results from complex interactions between environmen-
tal and genetic factors [1]. More and more studies have
focused on the role of gene polymorphism in the aeti-
ology of cancers. Recently, there is growing evidence
that single nucleotide polymorphism (SNP) plays an im-
portant role in carcinogenesis [2,3]. DNA repair systems
have been considered to maintain genomic integrity by
counting threats posed by DNA lesions. Deficiency
in the DNA repair pathways might make these lesions
unrepaired or repaired incorrectly, eventually leading to* Correspondence: ghzhen@tjh.tjmu.edu.cn
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reproduction in any medium, provided the orgenome instability or mutations which may contribute
directly to cancer.
RAD51 gene is located on chromosome 15q15.1 in
humans [4]. The RAD51 protein encoding by RAD51
gene is essential for the repair of DNA damage. Growing
evidences show that RAD51 has an irreplaceable role in
the maintenance of genomic stability and the repair of
DNA double-strand breaks [5]. The RAD51 genetic vari-
ations may contribute to the development of cancers [6].
A functional single nucleotide polymorphism, 135G/C
(rs1801320), has been identified in the 5′ untranslated re-
gion of the RAD51 gene [7] and has been reported to affect
gene transcription activity [8].
Up to now, a variety of molecular epidemiological studies
have been conducted to estimate the association between
the RAD51 135G/C polymorphism and risk of various can-
cers [9-17], including squamous cell carcinoma of the headLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[26-28] and acute leukaemia [29-37]. However, the results
of previous studies on the association between RAD51
135G/C polymorphism and cancer risk have been incon-
clusive, partially because of the relatively small sample
size of most studies. Therefore, we carried out this meta-
analysis to evaluate the association between RAD51 135G/
C polymorphism and risk of the four common types of
cancers.
Methods
Selection of eligible studies
We conducted a comprehensive search in Pubmed,
Cochrane library and Chinese Biomedical Literature Data-
base (CBM), covering all articles published up to Oct 31,
2013, using the following terms: “RAD51” AND “poly-
morphism” AND “(squamous cell carcinoma of the head
and neck) OR (colorectal cancer) OR (ovarian cancer) OR
(acute leukaemia)”. References of all identified studies and
reviews were examined for additional articles.
Study assessment
Included studies in this meta-analysis met the following
criteria: (a) a human case-control study on the associ-
ation between RAD51 135G/C polymorphism and any of
the four common cancers; (b) containing available geno-
type data in cases and controls for estimating an odds
ratio (OR) and 95% confidence interval (CI); (c) geno-
type distributions of control population were consistent
with Hardy-Weinberg equilibrium (HWE). The exclu-
sion criteria were: (a) reviews, letters, editorial articles
and case reports; (b) studies involving only a case popu-
lation; (c) research not providing cancer information.
Data extraction
Two investigators (Cheng and Shi) extracted the data
from all of the eligible publications according to the in-
clusion and exclusion criteria mentioned above. Primary
extraction data were reviewed by Zhen, and any dis-
agreement was resolved by discussion among the three
authors. From each study, the following information was
collected: first author’s name, year of publication, study
location, cancer type, sample size, source of control, the
genotyping method, the number of genotype frequencies
in cases and controls.
Statistical analysis
For each case-control study, we first examined whether
the genotype frequencies in controls were consistent
with HWE. ORs and 95% CIs were calculated as a meas-
ure of the association between the RAD51 135G/C gene
polymorphism and risk of the four cancers. The pooled
ORs were performed for the homozygote comparison
(G/G vs. C/C), heterozygote comparison (G/C vs. C/C),dominant (G/G + G/C vs. C/C) and recessive (G/G vs.
G/C + C/C) genetic model comparison, and the signifi-
cances of the summary ORs were determined by Z test,
P < 0.05 was considered as statistically significant. The
chi-square-based Q-test was used to assess the statistical
heterogeneity among studies, and it was considered sig-
nificant if P < 0.10 [38]. If the P value greater than 0.10,
indicating the absence of heterogeneity, then a fixed-
effects model (the Mantel-Haenszel method) was applied
to calculate the summary ORs [39]. Otherwise, the
random-effects model (the DerSimonian and Laird
method) was used [40]. I2 was also calculated to test het-
erogeneity among included studies, with I2 < 25%, 25-
75%, and >75% considered to represent low, moderate
and high degree of heterogeneity, respectively [41]. Sen-
sitivity analysis was performed to estimate the stability
of the results, each study involved in this meta-analysis
was deleted each time to reflect the influence of the in-
dividual data set to pooled ORs. Publication bias within
the literature was assessed using Begg’s test [42], an
asymmetric funnel plot showed a potential publication
bias. Egger’s linear regression test (P < 0.05 was consid-
ered significant publication bias) was also used to evalu-
ate the symmetry of the funnel plot [43]. All of the
analyses were carried out with RevMan 5.0.23 (Cochrane
Library Software, Oxford, UK) and STATA11.0 (STATA
Corporation, College Station, TX, USA).
Results
Study characteristics
A total of 133 related publications were identified, of
which 19 studies were not accepted since they were not
full articles (6 reviews, 7 meta-analysis, 4 comments, 2
case-reports). Fifty-nine articles were not about the
above four cancers, 33 publications were excluded be-
cause they did not meet the inclusion criteria (11 not
case-control studies, 6 not human studies, 7 not present
the usable data, 7 not the gene loci, 2 not about poly-
morphism research). Finally, 22 studies including 6836
cases and 8507 controls were included in this meta-
analysis (Figure 1).
The main characteristics of these 22 included studies
are summarized in Table 1. There were 14 studies from
European countries, 3 studies from Asian countries, 3
studies from American countries, 1 study from Australia
and 1 study from Africa. In addition, 9 articles were
population-based and 13 articles were hospital-based.
The number of publications on SCCHN, colorectal,
ovarian cancer and acute leukaemia were 4, 4, 5, and 9,
respectively. The diagnosis of most of the cases was
based on pathology. Healthy subjects matched for age
and sex were used as controls. Polymerase chain reac-
tion (PCR) or restriction fragment length polymorphism
(RFLP) were performed as genotyping methods. The
Figure 1 Flow diagram of study selection.
Table 1 Characteristics of 22 published studies included in this meta-analysis
First author Year Study location Cancer type Sample size Source of controls Genotyping methods
1. Lu JC 2006 USA SCCHN 716/719 HCC PCR-RFLP
2. Gil J 2011 Poland CC 133/100 HCC PCR-RFLP
3. Webb PM 2005 Australia OC 548/335 PCC PCR
4. Gresner P 2012 Poland SCCHN 81/111 PCC PCR
5. Seedhouse C 2004 UK AL 267/186 PCC PCR
6. Jawad M 2006 UK AL 267/186 PCC PCR
7. Krupa R 2011 Poland CC 100/100 HCC PCR
8. Sliwinski T 2010 Poland SCCHN 288/353 HCC PCR-RFLP
9. Hamdy MS 2011 Egypt AL 50/30 HCC PCR-RFLP
10. Liu L 2011 China AL 625/704 HCC PCR
11. Romanowicz-MakowskaH 2012 Poland CC 320/320 HCC PCR
12. WerbouckJ 2008 Belgium SCCHN 152/157 HCC PCR
13. Romanowicz-MakowskaH 2011 Poland OC 120/120 HCC PCR
14. Bhatla D 2008 USA AL 452/646 PCC PCR
15. Voso MT 2007 Italy AL 160/161 HCC PCR-RFLP
16. Mucha B 2012 Poland CC 200/200 HCC PCR-RFLP
17. Zhang ZQ 2009 China AL 166/458 HCC PCR-RFLP
18. Auranen A (UK) 2005 UK OC 729/847 PCC PCR
18. Auranen A (USA) 2005 USA OC 326/419 PCC PCR
18. Auranen A (Danish) 2005 Denmark OC 278/699 PCC PCR
21. Yang L 2011 China AL 379/704 HCC PCR
22. Rollinson S 2006 UK AL 479/952 PCC PCR
SCCHN: squamous cell carcinoma of the head and neck; CC: colorectal cancer; OC: ovarian cancer; AL: acute leukaemia; HCC: hospital-based case-control; PCC:
population-based case-control; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism.
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were shown in Table 2.
Quantitative synthesis
The evaluation of association between RAD51 135G/C
gene polymorphism and the risk of the four types of
cancers was summarized in Table 3. Overall, no signifi-
cant association was found between RAD51 135G/C
gene polymorphism and the risk of the four cancers (G/
G vs. C/C: OR = 0.83, 95%CI = 0.43-1.59, P = 0.57; G/C
vs. C/C: OR = 0.90, 95%CI = 0.39-2.08, P = 0.81; G/G +
G/C vs. C/C: OR = 0.82, 95%CI = 0.39-1.73, P = 0.60; G/
G vs. G/C + C/C: OR = 0.84, 95%CI = 0.69-1.02, P = 0.08).
However, in the subgroup analysis by cancer type, there
was a significant association between this polymorphism
and SCCHN under homozygote comparison (G/G vs. C/
C: OR = 2.46, 95%CI = 1.08-5.61; P = 0.03) (Figure 2).
There was no significant association between this poly-
morphism and the risk of other three cancers under all
comparisons. In the subgroup analyses by ethnicity or
source of controls, no significant association was found
in different genetic models.Table 2 Distribution of RAD51 genotype and allele among ca
First author Year Case GC CC Con
GG GG
1. Lu JC 2006 624 91 1 622
2. Gil J 2011 100 29 4 73
3. Webb PM 2005 457 85 4 971
4. Gresner P 2012 67 13 1 71
5. Seedhouse C 2004 210 44 3 166
6. Jawad M 2006 210 44 3 166
7. Krupa R 2011 61 36 3 36
8. Sliwinski T 2010 138 145 5 258
9. Hamdy MS 2011 39 9 2 26
10. Liu L 2011 72 25 8 511
11. Romanowicz- MakowskaH 2012 51 56 213 91
12. Werbouck J 2008 136 15 1 134
13. Romanowicz-MakowskaH 2011 13 15 92 33
14. Bhatla D 2008 374 73 5 555
15. Voso MT 2007 125 33 2 142
16. Mucha B 2012 161 34 5 157
17. Zhang ZQ 2009 117 47 2 315
18. Auranen A (Danish) 2005 241 36 1 616
18. Auranen A (UK) 2005 642 84 3 745
18. Auranen A (USA) 2005 270 52 4 357
21. Yang L 2011 268 101 10 511
22. Rollinson S 2006 431 34 1 817
HWE: P value for Hardy-Weinberg equilibrium for RAD51 135G/C polymorphism amTest of heterogeneity
For the comprehensive analysis, the I2 showed a stable
variation under all comparisons (G/G vs. C/C: P <
0.00001, I2 = 81%; G/C vs. C/C: P < 0.00001, I2 = 89%; G/
G + G/C vs. C/C: P < 0.00001, I2 = 88%; G/G vs. G/C +
C/C: P < 0.00001, I2 = 78%). In the subgroup analyses of
SCHNN and acute leukaemia, the I2 showed a low or
moderate variation under all comparisons. In the sub-
group analyses of colorectal cancer and ovarian cancer,
under most comparisons, the moderate heterogeneity
was detected. For source of controls, there was no signifi-
cant heterogeneity under all comparisons of population-
based case-control (PCC), except for heterozygous and
dominant model comparisons (G/C vs. C/C: P < 0.00001,
I2 = 93%; G/G +G/C vs. C/C: P < 0.00001, I2 = 92%) in
hospital-based case-control (HCC). P value for heterogen-
eity was not significant under all comparisons in the sub-
group analyses of Asian population, but in Caucasian
group, there were high degree heterogeneity under hetero-
zygous and dominant model comparisons (G/C vs. C/C:
P < 0.00001, I2 = 90%; G/G + G/C vs. C/C: P < 0.00001,
I2 = 89%).ncer patients and controls
trol GC CC Case C Control C HWE
G G
96 1 1339 93 1340 98 0.17
27 0 229 37 173 27 0.19
145 10 999 93 2087 165 0.08
14 2 147 15 156 18 0.22
18 2 464 50 350 22 0.08
18 2 464 50 350 22 0.08
35 29 158 42 107 93 0.003
64 32 421 155 580 128 0.28
3 1 87 13 55 5 0.06
175 18 169 25 1197 211 0.52
164 65 158 482 346 294 0.57
23 0 287 17 291 23 0.32
69 18 41 199 135 105 0.07
85 6 821 83 1195 97 0.18
18 1 283 37 302 20 0.61
37 6 356 44 351 49 0.05
123 20 281 51 753 163 0.08
78 5 518 38 1310 88 0.15
100 2 1368 90 1590 104 0.48
61 1 592 60 775 63 0.34
175 18 637 121 1197 211 0.52
115 4 896 36 1749 123 0.98
ong controls.
Table 3 Total and stratified analysis of the RAD51 135G/C polymorphism on risk of the four cancers
Variables No.a Case/Control GG vs. CC GC vs. CC GG+GC vs. CC GG vs. GC+CC
OR(95% CI) Pb P OR(95% CI) Pb P OR(95% CI) Pb P OR(95% CI) Pb P
Total cancer types 22 6836/8507 0.83(0.43–1.59) 0.00c 0.57 0.90(0.39–2.08) 0.00c 0.81 0.82(0.39–1.73) 0.00c 0.60 0.84(0.69–1.02) 0.00c 0.08
SCCHN 4 1237/1340 2.46(1.08–5.61) 0.50 0.03 2.20(0.30–16.22) 0.02 0.44 2.50(0.76–8.28) 0.25 0.13 0.84(0.40–1.75) 0.00c 0.64
CC 4 753/720 0.92(0.08–10.55) 0.00c 0.95 0.65(0.05–8.08) 0.00c 0.74 0.79(0.06–10.16) 0.00c 0.85 1.12(0.53–2.35) 0.00c 0.77
OC 5 2001/2420 0.42(0.10–1.78) 0.0007 0.24 0.41(0.06–2.67) 0.00c 0.35 0.40(0.07–2.18) 0.00c 0.29 0.80(0.62–1.03) 0.07 0.09
AL 9 2845/4027 0.82(0.49–1.39) 0.26 0.47 1.00(0.59–2.08) 0.29 0.99 0.85(0.50–1.44) 0.25 0.60 0.82(0.63–1.07) 0.002 0.14
Source of controls
HCC 13 3409/4126 0.77(0.30–1.98) 0.00c 0.58 0.79(0.24–2.60) 0.00c 0.70 0.74(0.26–2.13) 0.00c 0.58 0.82(0.60–1.12) 0.00c 0.20
PCC 9 3427/4381 0.93(0.53–1.62) 0.87 0.79 1.14(0.64–2.02) 0.87 0.66 0.95(0.54–1.67) 0.88 0.87 0.88(0.71–1.09) 0.01 0.25
Ethnicity
Asian 3 1170/1866 0.92(0.27–3.19) 0.01 0.90 0.98(0.28–3.40) 0.01 0.97 0.94(0.27–3.26) 0.009 0.92 0.94(0.77–1.14) 0.64 0.52
Caucasian 18 5616/6611 0.80(0.36–1.79) 0.00c 0.59 0.86(0.31–2.38) 0.00c 0.77 0.79(0.32–1.95) 0.00c 0.61 0.83(0.65–1.05) 0.00c 0.13
African 1 50/30 0.75(0.06–8.70) 0.82 1.50(0.10–23.07) 0.77 0.83(0.07–9.54) 0.88 0.55(0.16–1.90) 0.34
aNumber of studies.
bP value of Q-test for heterogeneity test.
cFixed-effects model was used when P value for heterogeneity test <0.10, otherwise, random-effects model was used.
















Figure 2 The association between RAD51 135G/C polymorphism and the four common cancers risk in the subgroup analysis by cancer
type (GG vs. CC).
Figure 3 Begg’s funnel plot for publication bias in selection of studies on RAD51 135G/C polymorphism (GG vs. CC; P for bias = 0.248).
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Sensitivity analyses were performed to assess the stability
of the results in this meta-analysis. Statistically similar
data were obtained after sequentially excluding each study,
indicating that our results were statistically reliable.Publication bias
Begg’s funnel plot and Egger’s test were used to assess
the publication bias of included studies. Publication bias
was not observed in Begg’s funnel plot. The shape of the
funnel plots showed to be symmetrical (G/G vs. C/C)
and the Egger’s test did not show any evidence of publi-
cation bias (P = 0.248 for G/G vs. C/C) (Figure 3). These
data indicate that there is no significant publication bias
in this meta-analysis.Discussion
The RAD51 protein encoding by RAD51 gene is essen-
tial for the repair of DNA damage. A number of original
studies have reported the association between RAD51
135G/C polymorphism and the risk of cancer with in-
conclusive results, These inconsistent results are possibly
because of a small effect of the polymorphism on can-
cers risk or the relatively low statistical power of the
published studies. To better understanding of this asso-
ciation,a meta-analysis, which potentially investigates a
large number of individuals and could estimate the effect
of a genetic factor on the risk of cancers, was needed to
provid a quantitative approach for combining the results
of various studies with the same topic, and for estimat-
ing and explaining their diversity [44,45]. We performed
a meta-analysis including 6836 cases and 8507 controls
from 22 case-control studies to evaluate the association
between RAD51 135G/C polymorphism and risk of
SCCHN, colorectal cancer, ovarian cancer and acute
leukaemia.
The overall population analysis showed no significant
association between RAD51 135G/C polymorphism and
risk of SCCHN, colorectal cancer, ovarian cancer and
acute leukaemia in any genetic model. However, in the
subgroup analysis by cancer type, we found that the
135G/C polymorphism of the RAD51 gene was associ-
ated with a significantly increased SCCHN risk. There
was an aggregated OR of 2.46 (95% CI = 1.08-5.61) for in-
creased SCCHN susceptibility under homozygote compari-
son. This indicates that the RAD51 135G/C polymorphism
may contribute to pathogenesis of SCCHN. GG genotype
has been reported to enhance RAD51 gene transcription
activity [8], individuals with GG genotype may be more
likely to develop SCCHN than those with CC or GC geno-
type. No associations were found between this polymorph-
ism and the risk of colorectal cancer, ovarian cancer andacute leukaemia, which was consistent with previous re-
ports [22,23,27-29,32,36].
Heterogeneity is one of the important issues in per-
forming a meta-analysis. In the present meta-analysis,
heterogeneity was found in almost all comparisons. Using
random-effect models and the stratified analyses by cancer
type, sources of control and ethnicity, the heterogeneity
was significantly decreased in most of the comparisons.
The sensitivity analysis did not alter the results of our
meta-analysis, indicating the results are stable. Meanwhile,
the publication bias for the association between RAD51
135G/C polymorphism and the risk of the four types of
cancers were not detected.
The present meta-analysis has some limitations. First,
the control subjects were not uniformly defined. Selection
bias and classification bias were possible because the in-
cluded controls may have other different risks of develop-
ing cancers. Second, in the subgroup analyses, the sample
sizes of Asian and African population were relatively
small, not having enough statistical power to explore the
real association. Third, cancer is a multi-factorial disease,
our meta-analysis was based on unadjusted estimates.
In conclusion, the GG genotype of RAD51 135G/C was
associated with a significantly increased risk of SCCHN.
However, there was no significant association between this
polymorphism and colorectal cancer, ovarian cancer or
acute leukaemia susceptibility.
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